Wang Ze, Wang Yapeng, Wang Shuo, Ran Qiang, Peng Song, Zhang Yao, Zhang Jun, Zhang Dianzheng, Wang Luofu, Lan Weihua, Liu Qiuli, Jiang Jun
Department of Urology, Daping Hospital, Army Medical University, Chongqing, China.
Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA.
Ann Med Surg (Lond). 2023 Nov 20;86(1):245-251. doi: 10.1097/MS9.0000000000001533. eCollection 2024 Jan.
The feasibility of combined tislelizumab with gemcitabine and cisplatin as a neoadjuvant regimen for muscle-invasive bladder cancer (MIBC) remains to be investigated.
The neoadjuvant treatment not only shrunk tumours significantly but also lowered their stages from T4bN1M0, T3N0M0, and T3bN0M0 to pT1, pT0 and pTis, respectively. The treatment suppressed tumour cell proliferation and promoted luminal-to-basal transition.
MIBC is an aggressive bladder cancer with poor prognosis. All three patients with MIBC benefited greatly from the neoadjuvant regimen (tislelizumab + gemcitabine + cisplatin). It appears that the effect of the treatment is independent of the levels of programmed death-ligand 1 nor the subtype of urothelial bladder cancer.
Combination of tislelizumab with gemcitabine and cisplatin appeared to be a safe and efficacious neoadjuvant therapy for MIBC.
替雷利珠单抗联合吉西他滨和顺铂作为肌肉浸润性膀胱癌（MIBC）新辅助治疗方案的可行性仍有待研究。
新辅助治疗不仅使肿瘤显著缩小，还分别将其分期从T4bN1M0、T3N0M0和T3bN0M0降至pT1、pT0和pTis。该治疗抑制肿瘤细胞增殖并促进管腔向基底的转变。
MIBC是一种侵袭性膀胱癌，预后较差。所有三名MIBC患者都从新辅助治疗方案（替雷利珠单抗+吉西他滨+顺铂）中受益匪浅。似乎该治疗效果与程序性死亡配体1水平及膀胱尿路上皮癌亚型无关。
替雷利珠单抗联合吉西他滨和顺铂似乎是一种安全有效的MIBC新辅助治疗方法。
